What p53 “reactivator” patent does Merck/ MSD relate to?
Merck/MSD’s well-known p53-reactivator efforts are tied to its small-molecule program commonly referenced around PC14586/“idasanutlin-like” p53 pathway approaches, but “p53 reactivator” is a broad label and can also be used by different companies for different mechanisms (MDM2 inhibitors vs. direct p53 reactivators). With only the query provided, there isn’t enough context to identify the specific Merck/MSD compound and the exact patent publication(s) you’re looking for.
Which Merck/MSD p53-reactivator compounds are most often mentioned?
In the p53 pathway space, “p53 reactivator” language frequently points to two different buckets that have very different patent landscapes:
- MDM2 inhibitors (seek to stabilize/restore p53 activity by blocking p53 degradation; these include products such as idasanutlin in the category, and related next-gen chemotypes).
- Direct p53 reactivators (attempt to reactivate mutant p53 using small molecules; these are less common at Merck/MSD versus MDM2-focused work).
To find the correct patent, you usually need at least one of the following: the compound code, brand/INN, lead molecule name, or a DrugPatentWatch.com entry or patent number.
How can you quickly identify the exact patent if you know the compound name?
If you share the compound code (for example, the internal lead name) or an external identifier, I can narrow to:
- the most relevant patent family
- the active/exclusive term drivers (filing date, priority date, patent term adjustments where applicable, and any exclusivity layers)
- likely expiration timing in key markets
A practical route is to look up the specific compound on DrugPatentWatch.com, which is designed to connect compounds to patents and key dates. You can start from the compound page and then follow the patent list there:
- DrugPatentWatch.com: https://www.drugpatentwatch.com/
When does a Merck/MSD p53-reactivator patent expire?
Patent expiration depends on the exact patent family and country/region (US vs. EP vs. UK vs. other jurisdictions). Even within the same compound program, different patents can expire at different times (for example, composition-of-matter vs. formulation vs. method-of-use claims).
If you tell me the specific compound name/code (or paste the DrugPatentWatch link), I can compute the likely expiration window from the patent-publication record and the listed expiry dates.
Are there patent challenges or competitors in this space?
P53-pathway oncology patents often face follow-on challenges (or are pressured by competing MDM2 inhibitors and newer-generation p53 reactivation approaches). The details again depend on the specific Merck/MSD patent family—composition-of-matter patents tend to draw different scrutiny than later-life-cycle patents.
Sharing the compound or link would let me map the competitive/patent landscape more precisely.
---
What I need from you to answer with the correct Merck/MSD patent
Reply with any one of the following:
1) the compound name or code (e.g., the Merck/MSD internal lead), or
2) the DrugPatentWatch.com link you mean, or
3) the patent number/publication number, or
4) the disease indication and any stage (clinical/approved), if known.
Once I have that, I’ll identify the specific Merck/MSD p53-reactivator patent(s) and the key expiration dates.
Sources cited:
- [1] https://www.drugpatentwatch.com/